Autolus Therapeutics (AUTL) Tops Q2 EPS by 8c
Tweet
Share
E-mail
Get Alerts AUTL Hot Sheet
Join SI Premium – FREE
Autolus Therapeutics (NASDAQ: AUTL) reported Q2 EPS of ($0.15), $0.08 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $45.69 million versus the consensus estimate of $30.08 million.
For earnings history and earnings-related data on Autolus Therapeutics (AUTL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pizza Hut CEO Aaron Powell resigns
- UBS Assumes SM Prime Holdings, Inc (SMPH:PM) (SPHXF) at Buy
- UBS Upgrades Zhejiang Leapmotor Technology (9863:HK) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
